Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Accenture plc (ACN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Accenture plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Accenture plc trades at $138.46 (market cap $86.98B). The key difference: Accenture plc is far larger — about 19.4× ACADIA Pharmaceuticals Inc.'s market cap, and Accenture plc pays a 4.59% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ACN | |
|---|---|---|
Market Cap | $4.49B | $86.98B |
Sector | Health | Technology |
52-Week High | $28.06 | $303.33 |
52-Week Low | $20.06 | $124.41 |
Enterprise Value | $3.69B | $85.20B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →
